التفاصيل البيبلوغرافية
| العنوان: |
Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. |
| المؤلفون: |
Blanes, Margarita1,2 (AUTHOR), de la Rubia, Javier1 (AUTHOR) delarubia_jav.@gva.es, Lahuerta, Juan J.3 (AUTHOR), González, José D.4 (AUTHOR), Ribas, Paz5 (AUTHOR), Solano, Carlos6 (AUTHOR), Alegre, Adrián7 (AUTHOR), Sanz, Miguel A.1 (AUTHOR) |
| المصدر: |
Leukemia & Lymphoma. Feb2009, Vol. 50 Issue 2, p216-222. 7p. 4 Charts, 2 Graphs. |
| مصطلحات موضوعية: |
*STEM cell transplantation, *TRANSPLANTATION of organs, tissues, etc., *B cell lymphoma, *DISEASES, *MULTIPLE myeloma |
| مستخلص: |
We evaluated the toxicity and outcome of a conditioning regimen comprising intravenous (iv) busulfan (BU) and melphalan (MEL) in 55 patients (median age, 61 years; range, 34-71) with multiple myeloma (MM) undergoing autologous stem-cell transplantation (ASCT). In 49 patients, this was the first ASCT. At transplant, 3 patients were in complete response (CR), 8 in near CR (nCR) and 30 in partial response (PR). The conditioning regimen comprised ivBU (3.2 mg/kg in a single daily dose, days -5 to -3) and MEL (140 mg/m2, day -2). Mucositis was the most frequent non-hematopoietic toxicity (47 patients). No patient developed sinusoidal occlusive syndrome. Febrile events were observed in 46 patients and were the cause of death in two (3.6%) transplant-related deaths. With a median follow-up of 15 months, 27 patients achieved CR/nCR (11 CR) and 21 a PR. The one-year actuarial overall and progression-free survival rates are 96% and 87%, respectively. This ivBU-containing regimen is associated with an acceptable toxicity and a high-response rate. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
